T. Rowe Price Investment Management, Inc. Biogen Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,169,970 shares of BIIB stock, worth $1.2 Billion. This represents 0.68% of its overall portfolio holdings.
Number of Shares
5,169,970
Previous 5,357,326
3.5%
Holding current value
$1.2 Billion
Previous $1.39 Billion
19.59%
% of portfolio
0.68%
Previous 0.9%
Shares
4 transactions
Others Institutions Holding BIIB
# of Institutions
1,046Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.84 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.76 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.28 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.56 Billion0.07% of portfolio
-
Wellington Management Group LLP Boston, MA5.12MShares$1.19 Billion0.2% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $33.4B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...